cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immunogen Inc
16 own
34 watching
Current Price
$14
$0.18
(1.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,164.98M
52-Week High
52-Week High
14.9051
52-Week Low
52-Week Low
3.095
Average Volume
Average Volume
3.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,164.98M
icon52-Week High14.9051
icon52-Week Low3.095
iconAverage Volume3.14M
iconDividend Yield--
iconP/E Ratio--
What does the Immunogen Inc do?
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Immunogen Inc make?
News & Events about Immunogen Inc.
Benzinga
24days ago
read more...
Stock Options Channel
25days ago
Investors in ImmunoGen, Inc. (IMGN) saw new options become available today, for the January 2025 expiration...
PR Newswire
26days ago
Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals? Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals? PR Newswire NEW YORK, May 3, 2023 NEW YORK...
PR Newswire
1month ago
Thinking about buying stock in ImmunoGen, Intel, Vuzix, eMagin, or Weibo? Thinking about buying stock in ImmunoGen, Intel, Vuzix, eMagin, or Weibo? PR Newswire NEW YORK, April 28, 2023 NEW YORK, April 28, 2023 /PRNewswire/ -- InvestorsObserverissues critical PriceWatch Alerts for IMGN, INTC, VUZI...
Business Wire
1month ago
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023. With a strong first full quarter of sales and continued...
Frequently Asked Questions
Frequently Asked Questions
What is Immunogen Inc share price today?
plus_minus_icon
Can Indians buy Immunogen Inc shares?
plus_minus_icon
How can I buy Immunogen Inc shares from India?
plus_minus_icon
Can Fractional shares of Immunogen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Immunogen Inc stocks?
plus_minus_icon
What is today’s traded volume of Immunogen Inc?
plus_minus_icon
What is today’s market capitalisation of Immunogen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Immunogen Inc?
plus_minus_icon
What percentage is Immunogen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Immunogen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$14
$0.18
(1.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00